A prospective metagenomic sequencing study searched for viral changes in children who developed islet autoimmunity or type 1 diabetes, revealing coxsackievirus ties to autoimmunity.
BTIG gave Centogene a Buy rating, while SVB Leerink and Evercore ISI each gave the company an Outperform rating.
Researchers compared single-cell transcriptomic and epigenetic profiles of healthy blood cells and leukemia samples to find a role for RUNX1 in disease.
The Genetron Health S5 NGS system is based on the Thermo Fisher Scientific Ion GeneStudio S5 and will be accompanied by Genetron-developed assays.
Yourgene said it continues to consider additional acquisition opportunities to enhance its earnings and to acquire complementary technologies.
Last week, GenomeWeb's readers were most interested in Oxford Nanopore's contention that Illumina's offer to license sequencing-related IP doesn't go far enough.
The companies aim to develop technologies for interpreting cancer genome data, with a focus on linking genetic profiles with treatment responses.
Biognosys will use its mass spectrometry technology to profile the proteome and phosphoproteome of clinical samples in Indivumed's oncology database.
In a notice posted on its website, the Competition and Markets Authority said it is extending its inquiry, with a new deadline of Feb. 5, 2020.
The financing will go toward building out its sales teams in the US and Europe in order to market its multiplexed MDx tests for infectious diseases.
A longitudinal household study suggests patients can acquire methicillin-resistant or sensitive Staphylococcus aureus from household members, pets, and surfaces.
Geisinger researchers will work with collaborators at the nonprofit FH Foundation to develop new methods for the identification and cascade testing of FH.
The partners are developing a new lab that will focus on research into protein biomarkers with medical, agricultural, and environmental applications.
A group led by Mount Sinai researchers said this methyltransferase, which is involved in sporulation, could be targeted to fight infections.
The test, which will be developed using the companies' respective technologies, will be marketed by Biolidics following clinical validation.
The firm's diagnostics and genomics group saw a 5 percent year-over-year revenue increase in the fourth quarter.
A regional court said certain 10x Genomics' products, including older GEM chips and some Chromium instruments, infringed a "utility model," similar to a patent.
PWNHealth will enable Stratify to offer its Prompt Personal Genetic Score prostate cancer genetic risk test directly to consumers with medical oversight.
A survey by University of Nebraska researchers found that both specialists and primary care healthcare providers largely interpreted genetic testing results correctly.
Researchers used single-cell sequencing to uncover developing brain cell populations from mice and humans with transcriptome features resembling those in pediatric brain tumors.
Using a single-nucleus RNA sequencing strategy, investigators tracked down cell type-specific gene expression and networks in Alzheimer's brains.
ONT called Illumina's revised remedies proposal an "illusory offer" that doesn't offset the anticompetitive effects of an Illumina-PacBio merger.
Asuragen will use its Amplidex PCR tech to develop companion diagnostics for Wave's investigational allele-selective therapeutic programs for Huntington's.
Last week, GenomeWeb's readers were most interested in the expansion of Illumina's offer to open sequencing-related IP held by Pacific Biosciences to competitors.
The company also said that it expects a clearance decision from US regulators in the near term on a lower respiratory tract infection test that runs on its Unyvero system.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.